Tauri receives medical domain contract from JPEO-CBD

The US Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD) has awarded a contract to Tauri Group for technical and programme management support services in the medical domain.

Awarded to six prime contractors including Tauri, the cumulative total of task orders for all awardees across domains could be nearly $495m in the next three years.

The Tauri Group managing partner Cos DiMaggio said the company has expertise in mitigating the effects of biological threats.

Tauri Group programme manager Ben Hagar added, "The Tauri team is prepared to hit the ground running to assist JPEO-CBD in developing and fielding medical countermeasures."

The company will provide technical expertise in the fields of microbiology, molecular biology, chemistry, biosurveillance, and engineering.

Additionally, relevant programme management experience to support navigating the US Department of Defense (DoD) acquisition and FDA regulations for medical countermeasure development, assay development and qualification, biological event situational awareness, and decision support will also be provided.

Responsible for research, development, acquisition, fielding, and life cycle support of CBD equipment and medical countermeasures, JPEO-CBD directs and manages the acquisition and fielding of chemical and biological detection and reconnaissance systems.

It also supports individual and collective protection systems, decontamination systems, information management systems, medical devices, drugs and vaccines, and installation and force protection systems.